Back to Oncology
Oncologyv2013Evidence-Based

Prognostic Index for Cancer Outcomes

Predicts cancer mortality from serum biomarkers using C-reactive protein (CRP) and white blood cell (WBC) count. This simple two-parameter scoring system provides risk stratification for cancer patients and helps guide prognostic discussions and clinical decision-making across multiple cancer types.

Clinical Input Parameters

mg/L
×10⁹/L
Clinical Assessment
Awaiting Parameters
prognostic index score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Prognostic Index for Cancer Outcomes is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Score = CRP points + WBC points (where CRP >10 mg/L = 1 point, WBC >11 × 10⁹/L = 1 point)

Clinical Pearls & Practice Notes

  • Simple two-parameter scoring system using readily available laboratory values
  • Validated across multiple cancer types and patient populations
  • Higher scores indicate worse prognosis due to increased systemic inflammation
  • Should be used in conjunction with other prognostic factors and clinical judgment
  • CRP reflects acute-phase response and tumor-associated inflammation
  • Elevated WBC count may indicate immune response to cancer or infection
  • Not a standalone diagnostic tool - requires integration with staging and other factors
  • Survival outcomes vary significantly depending on cancer type, stage, and treatment
  • May help guide prognostic discussions and treatment planning decisions
  • Regular monitoring of these biomarkers may help track disease progression
  • Cost-effective prognostic tool using standard laboratory tests
  • Particularly useful in settings where more complex scoring systems are unavailable

Evidence & Literature Citations

  1. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107(4):695-9. doi: 10.1038/bjc.2012.292.
  2. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633-41. doi: 10.1016/j.ejca.2011.03.028.
  3. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-40. doi: 10.1016/j.ctrv.2012.08.003.

Score Interpretation Ranges

Low Risk0 – 0 pts

Minimal inflammatory response

Intermediate Risk1 – 1 pts

Moderate inflammatory response

High Risk2 – 2 pts

Significant inflammatory response

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.